These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 24670538)

  • 1. Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.
    Meng XY; Zhang Q; Li Q; Lin S; Li J
    J Int Med Res; 2014 Jun; 42(3):619-27. PubMed ID: 24670538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coexpressed High Levels of VEGF-C and Active MMP-9 Are Associated With Lymphatic Spreading and Local Invasiveness of Papillary Thyroid Carcinoma.
    Šelemetjev S; Ðoric I; Paunovic I; Tatic S; Cvejic D
    Am J Clin Pathol; 2016 Nov; 146(5):594-602. PubMed ID: 27806941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma.
    Wu G; Zhou Y; Li T; Guo J; Zhou Z
    J Int Med Res; 2013 Jun; 41(3):816-24. PubMed ID: 23685894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma.
    Wang N; Jiang R; Yang JY; Tang C; Yang L; Xu M; Jiang QF; Liu ZM
    J Mol Histol; 2014 Aug; 45(4):391-9. PubMed ID: 24276590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].
    Wang T; Jiang CX; Li Y; Liu X
    Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):824-8. PubMed ID: 20193458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparity expression of gammaH2AX in papillary thyroid cancer and nodular goiter.
    Hu S; Zhang G; Xu J; Zhu X; Lu X; Jiang L; Wang Q; Hou X; Cao J; Ge M
    Clin Lab; 2014; 60(12):2031-7. PubMed ID: 25651738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma.
    Salajegheh A; Pakneshan S; Rahman A; Dolan-Evans E; Zhang S; Kwong E; Gopalan V; Lo CY; Smith RA; Lam AK
    Hum Pathol; 2013 Oct; 44(10):2204-12. PubMed ID: 23845470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer.
    Lin SY; Wang YY; Sheu WH
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):513-8. PubMed ID: 12641636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression patterns and clinical significance of estrogen receptor-α and β in papillary thyroid carcinoma.
    Huang Y; Dong W; Li J; Zhang H; Shan Z; Teng W
    BMC Cancer; 2014 May; 14():383. PubMed ID: 24884830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
    Jiang XL; Zhang H; Chen YL; Peng L
    Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
    [No Abstract]   [Full Text] [Related]  

  • 11. Expression of the NOB1 gene and its clinical significance in papillary thyroid carcinoma.
    Lin S; Meng W; Zhang W; Liu J; Wang P; Xue S; Chen G
    J Int Med Res; 2013 Jun; 41(3):568-72. PubMed ID: 23685895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Stuchi LP; Castanhole-Nunes MMU; Maniezzo-Stuchi N; Biselli-Chicote PM; Henrique T; Padovani Neto JA; de-Santi Neto D; Girol AP; Pavarino EC; Goloni-Bertollo EM
    Genes (Basel); 2020 Aug; 11(9):. PubMed ID: 32824922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma.
    Qing W; Fang WY; Ye L; Shen LY; Zhang XF; Fei XC; Chen X; Wang WQ; Li XY; Xiao JC; Ning G
    Thyroid; 2012 Sep; 22(9):905-10. PubMed ID: 22870901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.
    Zhang XJ; Su YR; Liu D; Xu DB; Zeng MS; Chen WK
    J Surg Res; 2014 Dec; 192(2):487-93. PubMed ID: 24974154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MMP-9-1562 C/T single nucleotide polymorphism associates with increased MMP-9 level and activity during papillary thyroid carcinoma progression.
    Roncevic J; Djoric I; Selemetjev S; Jankovic J; Dencic TI; Bozic V; Cvejic D
    Pathology; 2019 Jan; 51(1):55-61. PubMed ID: 30497805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.
    Jo YS; Li S; Song JH; Kwon KH; Lee JC; Rha SY; Lee HJ; Sul JY; Kweon GR; Ro HK; Kim JM; Shong M
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3667-70. PubMed ID: 16772349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
    Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
    Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF-C and COX-2 expression in papillary thyroid cancer.
    Siironen P; Ristimäki A; Narko K; Nordling S; Louhimo J; Andersson S; Haapiainen R; Haglund C
    Endocr Relat Cancer; 2006 Jun; 13(2):465-73. PubMed ID: 16728574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease.
    Su X; He C; Ma J; Tang T; Zhang X; Ye Z; Long Y; Shao Q; Shao J; Yang A
    PLoS One; 2016; 11(11):e0165596. PubMed ID: 27802347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.